ANG Lifesciences India share news, announcements and annual reports
BSE: 540694Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 2 Nov 2026. Previous close ₹32.09.
2 Nov: open ₹32.09, high ₹34.50, low ₹31.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43 Cr3,715th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.81
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −22.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −6.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.47
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,769
ANG Lifesciences India share news and announcements
374 announcements, routine notices left out, newest first. Page 2 of 8.
Nov 2024
14 Nov · Results
7 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Oct 2024
1 Oct · Disclosure under Regulation 30A of LODR
Sep 2024
Aug 2024
7 Aug · Board meeting
Meeting on 14 Aug 2024: quarterly results
Jun 2024
27 Jun · Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015.
May 2024
27 May · Announcement under Regulation 30 (LODR)-Meeting Updates
24 May · Board meeting
Meeting on 30 May 2024: audited results13 May · Announcement under Regulation 30 (LODR)-Meeting Updates
Apr 2024
30 Apr · Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
20 Apr · Compliance Certificate For The Year Ended 31.03.2024
9 Apr · Legal
Exchange has sought clarification from ANG Lifesciences India Ltd on April 8, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Feb 2024
7 Feb · Board meeting
Meeting on 14 Feb 2024: quarterly results1 Feb · Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
Jan 2024
31 Jan · Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (The 'Listing Regulations')
Dec 2023
Nov 2023
14 Nov · Board meeting
6 Nov · Board meeting
Meeting on 14 Nov 2023: quarterly results
Oct 2023
Sep 2023
8 Sep · Reg. 34 (1) Annual Report.
5 Sep · Board meeting
Aug 2023
29 Aug · Board meeting
Meeting on 5 Sep 2023: annual general meeting